Lamya Haddaoui

To the Editor, Secondary acute myeloid leukemia (AML), that is AML arising after prior exposure to cytotoxic therapy (tAML, therapy-related AML) and/or antecedent hematological disorder (AHD), has generally been associated with a worse prognosis in comparison to de novo AML. However, it is increasingly recognized that genetics rather than clinical history may explain these outcome differences [1-3].